nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—SLC6A4—chronic obstructive pulmonary disease	0.298	0.565	CbGaD
Nefazodone—HTR2A—chronic obstructive pulmonary disease	0.229	0.435	CbGaD
Nefazodone—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.032	0.147	CbGbCtD
Nefazodone—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.032	0.147	CbGbCtD
Nefazodone—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0286	0.131	CbGbCtD
Nefazodone—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0269	0.124	CbGbCtD
Nefazodone—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0182	0.0835	CbGbCtD
Nefazodone—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0173	0.0797	CbGbCtD
Nefazodone—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0154	0.071	CbGbCtD
Nefazodone—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0151	0.0695	CbGbCtD
Nefazodone—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0143	0.0657	CbGbCtD
Nefazodone—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00906	0.0417	CbGbCtD
Nefazodone—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00855	0.0393	CbGbCtD
Nefazodone—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.00604	0.392	CbGeAlD
Nefazodone—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00219	0.142	CbGeAlD
Nefazodone—SLC6A3—respiratory system—chronic obstructive pulmonary disease	0.000761	0.0494	CbGeAlD
Nefazodone—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.000697	0.0453	CbGeAlD
Nefazodone—Meclizine—CYP1A2—chronic obstructive pulmonary disease	0.000634	0.156	CrCbGaD
Nefazodone—SLC6A2—respiratory system—chronic obstructive pulmonary disease	0.000614	0.0399	CbGeAlD
Nefazodone—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000455	0.0296	CbGeAlD
Nefazodone—SLC6A3—lung—chronic obstructive pulmonary disease	0.000404	0.0262	CbGeAlD
Nefazodone—ADRA2A—connective tissue—chronic obstructive pulmonary disease	0.000382	0.0248	CbGeAlD
Nefazodone—Domperidone—CYP1A2—chronic obstructive pulmonary disease	0.000377	0.0926	CrCbGaD
Nefazodone—SLC6A4—lung—chronic obstructive pulmonary disease	0.00037	0.024	CbGeAlD
Nefazodone—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.000369	0.024	CbGeAlD
Nefazodone—ADRA2A—bronchus—chronic obstructive pulmonary disease	0.000357	0.0232	CbGeAlD
Nefazodone—SLC6A2—lung—chronic obstructive pulmonary disease	0.000326	0.0212	CbGeAlD
Nefazodone—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000325	0.0211	CbGeAlD
Nefazodone—ADRA2A—trachea—chronic obstructive pulmonary disease	0.000321	0.0208	CbGeAlD
Nefazodone—Aripiprazole—SLC6A4—chronic obstructive pulmonary disease	0.000319	0.0785	CrCbGaD
Nefazodone—Trazodone—SLC6A4—chronic obstructive pulmonary disease	0.000318	0.0782	CrCbGaD
Nefazodone—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000297	0.0193	CbGeAlD
Nefazodone—HTR2A—trachea—chronic obstructive pulmonary disease	0.000273	0.0177	CbGeAlD
Nefazodone—Zuclopenthixol—HTR2A—chronic obstructive pulmonary disease	0.000266	0.0653	CrCbGaD
Nefazodone—Aripiprazole—HTR2A—chronic obstructive pulmonary disease	0.000246	0.0603	CrCbGaD
Nefazodone—Trazodone—HTR2A—chronic obstructive pulmonary disease	0.000244	0.0601	CrCbGaD
Nefazodone—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000242	0.0157	CbGeAlD
Nefazodone—CYP3A5—lung—chronic obstructive pulmonary disease	0.000242	0.0157	CbGeAlD
Nefazodone—Fluphenazine—CYP1A2—chronic obstructive pulmonary disease	0.000235	0.0576	CrCbGaD
Nefazodone—Thioproperazine—HTR2A—chronic obstructive pulmonary disease	0.000233	0.0572	CrCbGaD
Nefazodone—ADRA2A—lung—chronic obstructive pulmonary disease	0.00023	0.015	CbGeAlD
Nefazodone—Fluphenazine—HTR2A—chronic obstructive pulmonary disease	0.000198	0.0486	CrCbGaD
Nefazodone—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000198	0.00105	CcSEcCtD
Nefazodone—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000198	0.00105	CcSEcCtD
Nefazodone—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000196	0.00105	CcSEcCtD
Nefazodone—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000196	0.00105	CcSEcCtD
Nefazodone—HTR2A—lung—chronic obstructive pulmonary disease	0.000196	0.0127	CbGeAlD
Nefazodone—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00104	CcSEcCtD
Nefazodone—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000195	0.00104	CcSEcCtD
Nefazodone—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000195	0.00104	CcSEcCtD
Nefazodone—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000194	0.00103	CcSEcCtD
Nefazodone—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.00103	CcSEcCtD
Nefazodone—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000194	0.00103	CcSEcCtD
Nefazodone—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000194	0.00103	CcSEcCtD
Nefazodone—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000193	0.00103	CcSEcCtD
Nefazodone—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000192	0.00102	CcSEcCtD
Nefazodone—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00102	CcSEcCtD
Nefazodone—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000192	0.00102	CcSEcCtD
Nefazodone—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00101	CcSEcCtD
Nefazodone—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00101	CcSEcCtD
Nefazodone—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00101	CcSEcCtD
Nefazodone—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00101	CcSEcCtD
Nefazodone—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00101	CcSEcCtD
Nefazodone—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.00019	0.00101	CcSEcCtD
Nefazodone—Infection—Formoterol—chronic obstructive pulmonary disease	0.000189	0.00101	CcSEcCtD
Nefazodone—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000189	0.00101	CcSEcCtD
Nefazodone—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.000999	CcSEcCtD
Nefazodone—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.000999	CcSEcCtD
Nefazodone—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.000999	CcSEcCtD
Nefazodone—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000188	0.000998	CcSEcCtD
Nefazodone—Trifluoperazine—CYP1A2—chronic obstructive pulmonary disease	0.000187	0.0461	CrCbGaD
Nefazodone—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.000996	CcSEcCtD
Nefazodone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000187	0.000993	CcSEcCtD
Nefazodone—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000187	0.000993	CcSEcCtD
Nefazodone—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000187	0.000993	CcSEcCtD
Nefazodone—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00099	CcSEcCtD
Nefazodone—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00099	CcSEcCtD
Nefazodone—Perphenazine—CYP1A2—chronic obstructive pulmonary disease	0.000185	0.0456	CrCbGaD
Nefazodone—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.000987	CcSEcCtD
Nefazodone—Infection—Montelukast—chronic obstructive pulmonary disease	0.000185	0.000987	CcSEcCtD
Nefazodone—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000184	0.000982	CcSEcCtD
Nefazodone—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.000977	CcSEcCtD
Nefazodone—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000183	0.000976	CcSEcCtD
Nefazodone—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000183	0.000973	CcSEcCtD
Nefazodone—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000183	0.000972	CcSEcCtD
Nefazodone—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000181	0.000961	CcSEcCtD
Nefazodone—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.000958	CcSEcCtD
Nefazodone—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.000958	CcSEcCtD
Nefazodone—ABCB1—trachea—chronic obstructive pulmonary disease	0.000179	0.0116	CbGeAlD
Nefazodone—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.000951	CcSEcCtD
Nefazodone—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.000948	CcSEcCtD
Nefazodone—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000178	0.000948	CcSEcCtD
Nefazodone—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000177	0.000943	CcSEcCtD
Nefazodone—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.000942	CcSEcCtD
Nefazodone—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.000935	CcSEcCtD
Nefazodone—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000174	0.000926	CcSEcCtD
Nefazodone—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000174	0.000926	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000174	0.000924	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.000924	CcSEcCtD
Nefazodone—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000172	0.000917	CcSEcCtD
Nefazodone—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000172	0.000917	CcSEcCtD
Nefazodone—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.000913	CcSEcCtD
Nefazodone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000171	0.000912	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00017	0.000905	CcSEcCtD
Nefazodone—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00017	0.000904	CcSEcCtD
Nefazodone—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.000904	CcSEcCtD
Nefazodone—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000169	0.000902	CcSEcCtD
Nefazodone—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.000902	CcSEcCtD
Nefazodone—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000169	0.000899	CcSEcCtD
Nefazodone—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000895	CcSEcCtD
Nefazodone—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.000895	CcSEcCtD
Nefazodone—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000168	0.000893	CcSEcCtD
Nefazodone—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.000893	CcSEcCtD
Nefazodone—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000168	0.000892	CcSEcCtD
Nefazodone—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000167	0.000889	CcSEcCtD
Nefazodone—Injury—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000884	CcSEcCtD
Nefazodone—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000166	0.000883	CcSEcCtD
Nefazodone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000166	0.000881	CcSEcCtD
Nefazodone—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.000879	CcSEcCtD
Nefazodone—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000164	0.000874	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.000873	CcSEcCtD
Nefazodone—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000163	0.000867	CcSEcCtD
Nefazodone—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.000867	CcSEcCtD
Nefazodone—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.000867	CcSEcCtD
Nefazodone—Pain—Formoterol—chronic obstructive pulmonary disease	0.000163	0.000867	CcSEcCtD
Nefazodone—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.000866	CcSEcCtD
Nefazodone—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000162	0.000864	CcSEcCtD
Nefazodone—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00086	CcSEcCtD
Nefazodone—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.000854	CcSEcCtD
Nefazodone—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.000851	CcSEcCtD
Nefazodone—Pain—Montelukast—chronic obstructive pulmonary disease	0.00016	0.00085	CcSEcCtD
Nefazodone—Thioproperazine—ALB—chronic obstructive pulmonary disease	0.000159	0.0391	CrCbGaD
Nefazodone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000159	0.000847	CcSEcCtD
Nefazodone—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.000843	CcSEcCtD
Nefazodone—Trifluoperazine—HTR2A—chronic obstructive pulmonary disease	0.000158	0.0389	CrCbGaD
Nefazodone—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000158	0.00084	CcSEcCtD
Nefazodone—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000158	0.000839	CcSEcCtD
Nefazodone—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.000837	CcSEcCtD
Nefazodone—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000157	0.000836	CcSEcCtD
Nefazodone—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000157	0.000836	CcSEcCtD
Nefazodone—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000157	0.000835	CcSEcCtD
Nefazodone—Perphenazine—HTR2A—chronic obstructive pulmonary disease	0.000156	0.0385	CrCbGaD
Nefazodone—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.000832	CcSEcCtD
Nefazodone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000156	0.000831	CcSEcCtD
Nefazodone—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000156	0.000829	CcSEcCtD
Nefazodone—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.000829	CcSEcCtD
Nefazodone—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.000819	CcSEcCtD
Nefazodone—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.000819	CcSEcCtD
Nefazodone—Quetiapine—HTR2A—chronic obstructive pulmonary disease	0.000153	0.0377	CrCbGaD
Nefazodone—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000153	0.000812	CcSEcCtD
Nefazodone—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000812	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000153	0.000812	CcSEcCtD
Nefazodone—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000151	0.000806	CcSEcCtD
Nefazodone—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000151	0.000806	CcSEcCtD
Nefazodone—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000151	0.000802	CcSEcCtD
Nefazodone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000151	0.000802	CcSEcCtD
Nefazodone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000151	0.000802	CcSEcCtD
Nefazodone—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000151	0.000802	CcSEcCtD
Nefazodone—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.00015	0.000799	CcSEcCtD
Nefazodone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00015	0.000799	CcSEcCtD
Nefazodone—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000149	0.000792	CcSEcCtD
Nefazodone—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000149	0.000792	CcSEcCtD
Nefazodone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000149	0.000792	CcSEcCtD
Nefazodone—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000148	0.000789	CcSEcCtD
Nefazodone—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.000789	CcSEcCtD
Nefazodone—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000148	0.000787	CcSEcCtD
Nefazodone—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000787	CcSEcCtD
Nefazodone—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000147	0.000785	CcSEcCtD
Nefazodone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000147	0.000785	CcSEcCtD
Nefazodone—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000784	CcSEcCtD
Nefazodone—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.000783	CcSEcCtD
Nefazodone—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.000777	CcSEcCtD
Nefazodone—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.000773	CcSEcCtD
Nefazodone—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000769	CcSEcCtD
Nefazodone—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.000761	CcSEcCtD
Nefazodone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.000757	CcSEcCtD
Nefazodone—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.000757	CcSEcCtD
Nefazodone—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00014	0.000747	CcSEcCtD
Nefazodone—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00014	0.000747	CcSEcCtD
Nefazodone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00014	0.000746	CcSEcCtD
Nefazodone—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.000745	CcSEcCtD
Nefazodone—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000744	CcSEcCtD
Nefazodone—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000137	0.000732	CcSEcCtD
Nefazodone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.000728	CcSEcCtD
Nefazodone—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000137	0.000728	CcSEcCtD
Nefazodone—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000135	0.000718	CcSEcCtD
Nefazodone—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000135	0.000718	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000716	CcSEcCtD
Nefazodone—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000713	CcSEcCtD
Nefazodone—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000707	CcSEcCtD
Nefazodone—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000706	CcSEcCtD
Nefazodone—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000132	0.000703	CcSEcCtD
Nefazodone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00013	0.000694	CcSEcCtD
Nefazodone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00013	0.000694	CcSEcCtD
Nefazodone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000129	0.000687	CcSEcCtD
Nefazodone—ABCB1—lung—chronic obstructive pulmonary disease	0.000128	0.00834	CbGeAlD
Nefazodone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000128	0.00068	CcSEcCtD
Nefazodone—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000127	0.000678	CcSEcCtD
Nefazodone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000126	0.000671	CcSEcCtD
Nefazodone—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000126	0.000671	CcSEcCtD
Nefazodone—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000123	0.000657	CcSEcCtD
Nefazodone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.000655	CcSEcCtD
Nefazodone—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000646	CcSEcCtD
Nefazodone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000121	0.000645	CcSEcCtD
Nefazodone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000121	0.000645	CcSEcCtD
Nefazodone—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00012	0.000639	CcSEcCtD
Nefazodone—Rash—Formoterol—chronic obstructive pulmonary disease	0.00012	0.000639	CcSEcCtD
Nefazodone—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00012	0.000639	CcSEcCtD
Nefazodone—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00012	0.000639	CcSEcCtD
Nefazodone—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000639	CcSEcCtD
Nefazodone—Headache—Formoterol—chronic obstructive pulmonary disease	0.000119	0.000635	CcSEcCtD
Nefazodone—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.000635	CcSEcCtD
Nefazodone—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000635	CcSEcCtD
Nefazodone—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.000634	CcSEcCtD
Nefazodone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000119	0.000633	CcSEcCtD
Nefazodone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000119	0.000632	CcSEcCtD
Nefazodone—Rash—Montelukast—chronic obstructive pulmonary disease	0.000118	0.000626	CcSEcCtD
Nefazodone—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000118	0.000626	CcSEcCtD
Nefazodone—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000624	CcSEcCtD
Nefazodone—Headache—Montelukast—chronic obstructive pulmonary disease	0.000117	0.000622	CcSEcCtD
Nefazodone—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000115	0.000615	CcSEcCtD
Nefazodone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000114	0.000609	CcSEcCtD
Nefazodone—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.000607	CcSEcCtD
Nefazodone—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.000605	CcSEcCtD
Nefazodone—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.000604	CcSEcCtD
Nefazodone—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000113	0.000604	CcSEcCtD
Nefazodone—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.000603	CcSEcCtD
Nefazodone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000113	0.000602	CcSEcCtD
Nefazodone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000113	0.000602	CcSEcCtD
Nefazodone—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.0006	CcSEcCtD
Nefazodone—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.000592	CcSEcCtD
Nefazodone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000111	0.00059	CcSEcCtD
Nefazodone—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000583	CcSEcCtD
Nefazodone—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000109	0.000581	CcSEcCtD
Nefazodone—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000572	CcSEcCtD
Nefazodone—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000107	0.000569	CcSEcCtD
Nefazodone—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000566	CcSEcCtD
Nefazodone—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000565	CcSEcCtD
Nefazodone—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000562	CcSEcCtD
Nefazodone—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000559	CcSEcCtD
Nefazodone—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000549	CcSEcCtD
Nefazodone—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000549	CcSEcCtD
Nefazodone—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.00054	CcSEcCtD
Nefazodone—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000536	CcSEcCtD
Nefazodone—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	9.97e-05	0.000531	CcSEcCtD
Nefazodone—Flushing—Prednisone—chronic obstructive pulmonary disease	9.79e-05	0.000521	CcSEcCtD
Nefazodone—Insomnia—Prednisolone—chronic obstructive pulmonary disease	9.33e-05	0.000497	CcSEcCtD
Nefazodone—Alopecia—Prednisone—chronic obstructive pulmonary disease	9.32e-05	0.000496	CcSEcCtD
Nefazodone—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	9.26e-05	0.000493	CcSEcCtD
Nefazodone—Pain—Prednisolone—chronic obstructive pulmonary disease	8.82e-05	0.00047	CcSEcCtD
Nefazodone—Vision blurred—Prednisone—chronic obstructive pulmonary disease	8.66e-05	0.000461	CcSEcCtD
Nefazodone—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	8.52e-05	0.000454	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	8.5e-05	0.000453	CcSEcCtD
Nefazodone—Anaemia—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000452	CcSEcCtD
Nefazodone—Agitation—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000449	CcSEcCtD
Nefazodone—Angioedema—Prednisone—chronic obstructive pulmonary disease	8.39e-05	0.000447	CcSEcCtD
Nefazodone—Malaise—Prednisone—chronic obstructive pulmonary disease	8.28e-05	0.000441	CcSEcCtD
Nefazodone—Vertigo—Prednisone—chronic obstructive pulmonary disease	8.25e-05	0.000439	CcSEcCtD
Nefazodone—Syncope—Prednisone—chronic obstructive pulmonary disease	8.24e-05	0.000439	CcSEcCtD
Nefazodone—Urticaria—Prednisolone—chronic obstructive pulmonary disease	8.2e-05	0.000436	CcSEcCtD
Nefazodone—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	8.07e-05	0.00043	CcSEcCtD
Nefazodone—Convulsion—Prednisone—chronic obstructive pulmonary disease	7.96e-05	0.000424	CcSEcCtD
Nefazodone—Hypertension—Prednisone—chronic obstructive pulmonary disease	7.93e-05	0.000422	CcSEcCtD
Nefazodone—Arthralgia—Prednisone—chronic obstructive pulmonary disease	7.82e-05	0.000416	CcSEcCtD
Nefazodone—Myalgia—Prednisone—chronic obstructive pulmonary disease	7.82e-05	0.000416	CcSEcCtD
Nefazodone—Anxiety—Prednisone—chronic obstructive pulmonary disease	7.79e-05	0.000415	CcSEcCtD
Nefazodone—Discomfort—Prednisone—chronic obstructive pulmonary disease	7.73e-05	0.000411	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	7.6e-05	0.000405	CcSEcCtD
Nefazodone—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	7.5e-05	0.000399	CcSEcCtD
Nefazodone—Oedema—Prednisone—chronic obstructive pulmonary disease	7.5e-05	0.000399	CcSEcCtD
Nefazodone—Infection—Prednisone—chronic obstructive pulmonary disease	7.45e-05	0.000397	CcSEcCtD
Nefazodone—Shock—Prednisone—chronic obstructive pulmonary disease	7.38e-05	0.000393	CcSEcCtD
Nefazodone—Tachycardia—Prednisone—chronic obstructive pulmonary disease	7.32e-05	0.00039	CcSEcCtD
Nefazodone—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	7.25e-05	0.000386	CcSEcCtD
Nefazodone—Anorexia—Prednisone—chronic obstructive pulmonary disease	7.15e-05	0.00038	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	6.83e-05	0.000364	CcSEcCtD
Nefazodone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	6.82e-05	0.000363	CcSEcCtD
Nefazodone—Insomnia—Prednisone—chronic obstructive pulmonary disease	6.78e-05	0.000361	CcSEcCtD
Nefazodone—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	6.73e-05	0.000358	CcSEcCtD
Nefazodone—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	6.6e-05	0.000351	CcSEcCtD
Nefazodone—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	6.52e-05	0.000347	CcSEcCtD
Nefazodone—Rash—Prednisolone—chronic obstructive pulmonary disease	6.5e-05	0.000346	CcSEcCtD
Nefazodone—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	6.5e-05	0.000346	CcSEcCtD
Nefazodone—Headache—Prednisolone—chronic obstructive pulmonary disease	6.46e-05	0.000344	CcSEcCtD
Nefazodone—Constipation—Prednisone—chronic obstructive pulmonary disease	6.41e-05	0.000341	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.18e-05	0.000329	CcSEcCtD
Nefazodone—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.13e-05	0.000326	CcSEcCtD
Nefazodone—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.13e-05	0.000326	CcSEcCtD
Nefazodone—Urticaria—Prednisone—chronic obstructive pulmonary disease	5.96e-05	0.000317	CcSEcCtD
Nefazodone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	5.93e-05	0.000316	CcSEcCtD
Nefazodone—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	5.93e-05	0.000316	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.52e-05	0.000294	CcSEcCtD
Nefazodone—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.38e-05	0.000286	CcSEcCtD
Nefazodone—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.3e-05	0.000282	CcSEcCtD
Nefazodone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.13e-05	0.000273	CcSEcCtD
Nefazodone—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.96e-05	0.000264	CcSEcCtD
Nefazodone—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.77e-05	0.000254	CcSEcCtD
Nefazodone—Rash—Prednisone—chronic obstructive pulmonary disease	4.73e-05	0.000252	CcSEcCtD
Nefazodone—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.72e-05	0.000251	CcSEcCtD
Nefazodone—Headache—Prednisone—chronic obstructive pulmonary disease	4.7e-05	0.00025	CcSEcCtD
Nefazodone—Nausea—Prednisone—chronic obstructive pulmonary disease	4.45e-05	0.000237	CcSEcCtD
Nefazodone—HTR2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.98e-05	0.000406	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.98e-05	0.000405	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.97e-05	0.000405	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.97e-05	0.000403	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	1.95e-05	0.000401	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	1.94e-05	0.000397	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.93e-05	0.000395	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.92e-05	0.000395	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.91e-05	0.000392	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.91e-05	0.000391	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.9e-05	0.000391	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.9e-05	0.00039	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.9e-05	0.000389	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.9e-05	0.000389	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.89e-05	0.000389	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.89e-05	0.000387	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.89e-05	0.000387	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.88e-05	0.000387	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	1.88e-05	0.000385	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.86e-05	0.000381	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.86e-05	0.000381	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.83e-05	0.000376	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.81e-05	0.000372	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.81e-05	0.000372	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.81e-05	0.000371	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.81e-05	0.000371	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.8e-05	0.000369	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	1.78e-05	0.000366	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.75e-05	0.000359	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.75e-05	0.000359	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.74e-05	0.000357	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.73e-05	0.000356	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.73e-05	0.000354	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.72e-05	0.000353	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.72e-05	0.000353	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.71e-05	0.000351	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.68e-05	0.000346	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.66e-05	0.00034	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.65e-05	0.000338	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.65e-05	0.000337	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.64e-05	0.000337	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.64e-05	0.000336	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.64e-05	0.000336	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.61e-05	0.000331	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.61e-05	0.00033	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.6e-05	0.000329	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.59e-05	0.000326	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.58e-05	0.000325	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	1.58e-05	0.000324	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	1.58e-05	0.000324	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.57e-05	0.000323	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.57e-05	0.000323	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.57e-05	0.000321	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.56e-05	0.00032	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.56e-05	0.00032	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	1.54e-05	0.000316	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.53e-05	0.000314	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	1.51e-05	0.00031	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.51e-05	0.000309	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.5e-05	0.000309	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.5e-05	0.000307	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.5e-05	0.000307	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.47e-05	0.000303	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.47e-05	0.000302	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.43e-05	0.000293	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.42e-05	0.000292	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.41e-05	0.00029	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	1.41e-05	0.000288	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.4e-05	0.000288	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.39e-05	0.000286	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.39e-05	0.000284	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.37e-05	0.000281	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.37e-05	0.000281	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.35e-05	0.000277	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.34e-05	0.000275	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.33e-05	0.000272	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.3e-05	0.000266	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.29e-05	0.000266	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.29e-05	0.000264	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	1.29e-05	0.000264	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.26e-05	0.000258	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.25e-05	0.000256	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.24e-05	0.000255	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.24e-05	0.000254	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.23e-05	0.000253	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.22e-05	0.000249	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.2e-05	0.000247	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.2e-05	0.000245	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.19e-05	0.000245	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.19e-05	0.000244	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.19e-05	0.000243	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.18e-05	0.000242	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.14e-05	0.000234	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.13e-05	0.000232	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.12e-05	0.00023	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.1e-05	0.000225	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.1e-05	0.000225	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.09e-05	0.000223	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.08e-05	0.000222	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.08e-05	0.000221	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.08e-05	0.000221	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.07e-05	0.00022	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.07e-05	0.000219	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.07e-05	0.000219	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.07e-05	0.000218	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.06e-05	0.000218	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.03e-05	0.000212	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.02e-05	0.00021	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.02e-05	0.000209	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.02e-05	0.000209	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.02e-05	0.000208	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.01e-05	0.000207	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1e-05	0.000206	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	9.98e-06	0.000205	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.92e-06	0.000204	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.9e-06	0.000203	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.77e-06	0.0002	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.76e-06	0.0002	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.72e-06	0.000199	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	9.72e-06	0.000199	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.71e-06	0.000199	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.66e-06	0.000198	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	9.44e-06	0.000194	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.41e-06	0.000193	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.39e-06	0.000193	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.34e-06	0.000192	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.31e-06	0.000191	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.3e-06	0.000191	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.3e-06	0.000191	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.25e-06	0.00019	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.23e-06	0.000189	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	9.16e-06	0.000188	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.1e-06	0.000187	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.09e-06	0.000187	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.04e-06	0.000185	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.95e-06	0.000184	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.9e-06	0.000183	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.69e-06	0.000178	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.64e-06	0.000177	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.62e-06	0.000177	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	8.46e-06	0.000174	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.44e-06	0.000173	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.44e-06	0.000173	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.4e-06	0.000172	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.39e-06	0.000172	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.27e-06	0.00017	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.27e-06	0.00017	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	8.21e-06	0.000168	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.21e-06	0.000168	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	8.11e-06	0.000166	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.9e-06	0.000162	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	7.76e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.68e-06	0.000158	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.63e-06	0.000157	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.5e-06	0.000154	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.47e-06	0.000153	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.37e-06	0.000151	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.35e-06	0.000151	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.34e-06	0.000151	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.14e-06	0.000147	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.11e-06	0.000146	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.04e-06	0.000144	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.94e-06	0.000142	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.86e-06	0.000141	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.83e-06	0.00014	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.82e-06	0.00014	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.8e-06	0.00014	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.78e-06	0.000139	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.64e-06	0.000136	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	6.56e-06	0.000135	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.51e-06	0.000134	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.51e-06	0.000133	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.49e-06	0.000133	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.47e-06	0.000133	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.47e-06	0.000133	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	6.4e-06	0.000131	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.2e-06	0.000127	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.17e-06	0.000127	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.13e-06	0.000126	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	6.12e-06	0.000125	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.04e-06	0.000124	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	5.99e-06	0.000123	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.89e-06	0.000121	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	5.86e-06	0.00012	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.77e-06	0.000118	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.77e-06	0.000118	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.74e-06	0.000118	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.62e-06	0.000115	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.61e-06	0.000115	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	5.61e-06	0.000115	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.52e-06	0.000113	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.51e-06	0.000113	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.5e-06	0.000113	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.49e-06	0.000113	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.46e-06	0.000112	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.36e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.23e-06	0.000107	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.22e-06	0.000107	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.19e-06	0.000107	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.12e-06	0.000105	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.99e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.97e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.88e-06	0.0001	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.74e-06	9.73e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.69e-06	9.62e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.66e-06	9.57e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.64e-06	9.53e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.6e-06	9.44e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.54e-06	9.31e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.54e-06	9.31e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.51e-06	9.25e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.47e-06	9.16e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	4.42e-06	9.07e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.42e-06	9.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.31e-06	8.85e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.3e-06	8.83e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.28e-06	8.78e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.23e-06	8.68e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.23e-06	8.67e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.22e-06	8.66e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.2e-06	8.61e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.17e-06	8.55e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.1e-06	8.42e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.1e-06	8.41e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.05e-06	8.31e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.02e-06	8.24e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.01e-06	8.22e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.99e-06	8.18e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.97e-06	8.14e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.72e-06	7.63e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.69e-06	7.56e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.65e-06	7.48e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.64e-06	7.47e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.57e-06	7.32e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.54e-06	7.27e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.52e-06	7.23e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.38e-06	6.94e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.37e-06	6.92e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.32e-06	6.8e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.24e-06	6.65e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.23e-06	6.62e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.09e-06	6.34e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.06e-06	6.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3e-06	6.15e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.8e-06	5.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.78e-06	5.71e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.74e-06	5.63e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.72e-06	5.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.61e-06	5.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.55e-06	5.23e-05	CbGpPWpGaD
